AAT-008 News - LARVOL Sigma

|||||||||| AAT-008 / AskAt, Ikena Oncology
Preclinical, Journal: Biological effects of prostaglandin E2-EP4 antagonist (AAT-008) in murine colon cancer in vivo: enhancement of immune response to radiotherapy and potential as a radiosensitizer. (Pubmed Central) - Mar 15, 2023
In the second FCM series, the mean Treg proportion and Teff/Treg ratio in the 0 mg + RT and 30 mg + RT groups were 4.0% and 1.5%, respectively (P=0.04) and 10 and 22, respectively (P=0.04). AAT-008 potentially enhances the radiosensitivity of colon cancer cells, apparently by stimulating the immune system against the cancer cells.

|||||||||| AAT-008 / AskAt, Kyn Therap
[VIRTUAL] Biological Effects of Prostagrandin E2-EP4 Antagonist (AAT-008): Enhancement of Immunoresponse to Radiotherapy and a Potential As a Radiosensitizer (Digital XP) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_2489;
It was assumed that the optimal dose of AAT-008 with RT was 10 mg/kg/day. It was suggested that AAT-008 stimulated the immune system against the cancer cells.

|||||||||| AAT-008 / AskAt, Kyn Therap
Journal: Biological Effects of Prostagrandin E2-EP4 Antagonist (AAT-008): Enhancement of Immunoresponse to Radiotherapy and a Potential as a Radiosensitizer. (Pubmed Central) - Oct 29, 2021
It was assumed that the optimal dose of AAT-008 with RT was 10 mg/kg/day. It was suggested that AAT-008 stimulated the immune system against the cancer cells.



	Diseases Companies Products Productz Mechanisms of Action Sites